{"id": "1346170432911790083", "creation": 1609787016.0, "user_id": "2402570365", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 0, "quote_count": 0}}, "text": "RT:@moneycontrolcom:#3PointAnalysis | Why is Bharat Biotech\u2019s \u2018Covaxin\u2019 receiving backlash post-approval? @sakshibatra18 explains: https://t.co/KhiUzE3W9R\n\n#COVID19 #COVAXIN #Vaccine @BharatBiotech https://t.co/r29dmSjN6W", "first_save": 1634559108.199414, "hashtags": ["#3POINTANALYSIS", "#COVID19", "#COVAXIN", "#VACCINE"]}